79 results about "Ventricular dysrhythmia" patented technology

Analyzes surface electrocardiographic and intracardiac signals to identify and separate electrical activity corresponding to distinct but superimposed events in the heart. Assesses the spatial phase, temporal phase, rate, spectrum and reproducibility of each event to determine uniformity of activation in all spatial dimensions. Uses numerical indices derived from these analyses to diagnose arrhythmias. Uses these indices to determine the location of an arrhythmia circuit, and to direct the movement of an electrode catheter to this location for ablation or permanent catheter positioning. Subsequently, uses these indices to determine whether ablation has successfully eliminated the circuit. Uses variability in these indices from the surface electrocardiogram to indicate subtle beat-to-beat fluctuations which reflect the tendency towards atrial and ventricular arrhythmias.

A cardiac rhythm management system includes an atrial pacing preference (APP) filter for promoting atrial pacing. The APP filter includes an infinite impulse response (IIR) or other filter that controls the timing of delivery of atrial pacing pulses. The atrial pacing pulses are delivered at an APP-indicated pacing rate that is typically at a small amount above the intrinsic atrial heart rate. For sensed beats, the APP indicated rate is increased until it becomes slightly faster than the intrinsic atrial heart rate. The APP-indicated pacing rate is then gradually decreased to search for the underlying intrinsic atrial heart rate. Then, after a sensed atrial beat, the APP filter again increases the pacing rate until it becomes faster than the intrinsic atrial rate by a small amount. As a result, most atrial heart beats are paced, rather than sensed. This decreases the likelihood of the occurrence of an atrial tachyarrhythima, such as atrial fibrillation. The decreased likelihood of atrial tachyarrhythmia, in turn, decreases the likelihood of inducing a ventricular arrhythmia, either as a result of the atrial tachyarrhythmia, or as the result of delivering a defibrillation shock to treat the atrial tachyarrhythmia.

A system and method for detecting and discriminating atrial arrhythmias based on mechanical signals of cardiac wall motion and electrical signals of cardiac depolarizations. A mechanical event rate determined from sensed mechanical events is used to corroborate an electrical event rate determined from sensed EGM or ECG signals to classify the heart rhythm. If the event rates are not correlated, other parameterized data from the mechanical signal and electrical signal are evaluated to detect evidence of an arrhythmia. If electrical and mechanical event data do not corroborate a common arrhythmia condition, electrical and mechanical sensing parameters may be adjusted.

A system and method for long-term monitoring of cardiac conditions such as arrhythmias is disclosed. The invention includes a pulse generator including means for sensing an arrhythmia. The pulse generator is coupled to at least one subcutaneous electrode or electrode array for providing electrical stimulation such as cardioversion / defibrillation shocks and / or pacing pulses. The electrical stimulation may be provided between multiple subcutaneous electrodes, or between one or more such electrodes and the housing of the pulse generator. In one embodiment, the pulse generator includes one or more electrodes that are isolated from the can. These electrodes may be used to sense cardiac signals.

The invention relates to a method and apparatus for predicting a sudden heart abnormality for an individual patient. In order to provide a prediction mechanism that is suitable for acute care, three sub-indices are determined based on medical data obtained from the patient. The first sub-index indicates the level of deterministic chaos in the heart rate variability of the patient, the second sub-index indicates the energy level in the myocardium of the patient, and the third sub-index indicates the degree of ventricular arrhythmia of the patient. Based on the first, second, and third sub-indices, at least one overall risk index is then determined, the overall risk index indicating the risk level of a sudden heart abnormality for the patient.

The present invention provides a system and a method for discriminating supraventricular tachyarrhythmias from ventricular arrhythmias during a tachycardia episode. First cardiac signals and second cardiac signals are sampled for cardiac complexes. A first feature on the first cardiac signal and a second feature on the second cardiac signal are utilized to determine an average time difference for a plurality of normal sinus rhythm complexes. A time difference between the first feature and the second feature is then determined for each cardiac complex of a tachycardiac rhythm. The cardiac complex is characterized as a ventricular tachycardia complex if the time difference exceeds the average time difference by a predetermined amount. Otherwise, it is classified as VT if its morphology after alignment is different from that during normal sinus rhythm.

A system and method for long-term monitoring of cardiac conditions such as arrhythmias is disclosed. The invention includes a pulse generator including means for sensing an arrhythmia. The pulse generator is coupled to at least one subcutaneous electrode or electrode array for providing electrical stimulation such as cardioversion / defibrillation shocks and / or pacing pulses. The electrical stimulation may be provided between multiple subcutaneous electrodes, or between one or more such electrodes and the housing of the pulse generator. In one embodiment, the pulse generator includes one or more electrodes that are isolated from the can. These electrodes may be used to sense cardiac signals.

Systems and methods define an index of risk for cardiac disease by detecting cellular derangements that may lead to cardiomyopathy, heart rhythm disorders or ischemic heart disease. The markers include fluctuations or abnormal rate-behavior of electrical, mechanical or other measurable biosignals. The invention operates in modes that can be applied to prevent atrial fibrillation or the risk for ventricular arrhythmias. Alternative embodiments are applied to tissue outside the heart such as skeletal muscle, smooth muscle, the central nervous system, the respiratory system, the urogenital system and the gastrointestinal system.

A method discriminates between ventricular arrhythmia and supraventricular arrhythmia by determining the direction of an electrical signal conducted through the atrioventricular node. An implantable cardiac defibrillator provides atrioventricular and ventriculoatrial pacing bursts to determine if an arrhythmia with a 1:1 atrial to ventricular relationship is due to ventricular tachycardia or supraventricular tachycardia. This discrimination capability reduces the incidence of inappropriate shocks from dual-chamber implantable cardiac defibrillators to near zero and provides a method to differentially diagnose supraventricular tachycardia from ventricular tachycardia.

Methods and apparatus for a three-stage ventricular cardioversion and defibrillation therapy that treats ventricular tachycardia and fibrillation at low energy levels. An implantable therapy generator adapted to generate and selectively deliver a three-stage ventricular therapy and at least two leads operably each having at least one electrode adapted to be positioned proximate the ventricle of the patient. The device is programmed to deliver a three-stage therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of a ventricular arrhythmia. The three-stage therapy includes a first stage for unpinning of one or more singularities associated with the ventricular arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities associated delivered via the near-field configuration of the electrodes.

Devices, systems and methods for controlling (inhibiting or enabling) the delivery of electrotherapeutic signals to a heart using sensing of local and / or global ECG signals to detect ventricular arrhythmia or indication of possible ventricular arrhythmia in the heart. The devices, systems and methods process the sensed signals and are capable of delivering electroptherapeutic signals to the heart in the presence of a supra-ventricular arrhythmia such as atrial fibrillation and atrial flutter, while inhibiting the delivering electroptherapeutic signals in the presence of PVCs and / or extopic beats, and / or ventricular arrhythmia. The electrotherapeutic signals may include, among others, pacing signals and cardiac contractility modulating signals.

The invention relates to a method and apparatus for predicting a sudden heart abnormality for an individual patient. In order to provide a prediction mechanism that is suitable for acute care, three sub-indices are determined based on medical data obtained from the patient. The first sub-index indicates the level of deterministic chaos in the heart rate variability of the patient, the second sub-index indicates the energy level in the myocardium of the patient, and the third sub-index indicates the degree of ventricular arrhythmia of the patient. Based on the first, second, and third sub-indices, at least one overall risk index is then determined, the overall risk index indicating the risk level of a sudden heart abnormality for the patient.

The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.

Methods and systems are disclosed for analyzing three dimensional orthogonal ECG measurements to assess patient risk of a subsequent cardiac event based on evaluation of cardiac vector values in view of risk factors defined by the invention.

The present invention provides a pacing device and method that allows for preferential right atrial, at or near the His bundle, and ventricular pacing, either individually or in combination, including tri-ventricular pacing. The pacing device includes a power source and one or more logic circuits allowing for programmable delivery of pacing to any combination of the right atria, the para-Hisian region, and the right and / or the left ventricles. The pacing device allows the user to select which site(s) to pace as well at the appropriate relative timing of pacing impulse delivery to any of these three previously mentioned sites. The device is constructed and arranged to be combined with an atrial sensing / pacing electrode to allow for atrio-ventricular sequential tri-ventricular pacing or variants of such. Also, a defibrillator lead can be incorporated into the device to allow for protection from ventricular arrhythmias and sudden death.

The present invention provides methods and materials for treating heart disorders, including heart failure and arrhythmia, by enhancing SERCA2a activity. Heart cells in a subject can be treated, for example, by introducing, into the heart of the subject, an adeno-associated virus subtype 6 (AAV6) viral delivery system that includes a functional nucleic acid encoding SERCA2a. For example, the functional nucleic acid encodes a non-viral therapeutic protein, thereby treating the subject.

A method and apparatus for treating malignant ventricular arrhythmias is provided. The apparatus includes a lead system that is placed subcutaneously in a patient and a pulse generator connected to lead system by lead. The lead system includes a plurality of energy delivery electrodes for delivering energy stimulation to a patient's heart and a plurality of monitoring electrodes for monitoring the occurrence of or sensing an arrhythmia. The lead system is encapsulated in a sheath of biocompatible material to prevent electrodes from contacting each other and shorting out or shorting together.

The present invention provides methods for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject. The present invention further provides methods for treating and preventing atrial and ventricular cardiac arrhythmias, heart failure, and exercise-induced sudden cardiac death in a subject. Additionally, the present invention provides use of JTV-519 in a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject who has, or is a candidate for, atrial fibrillation. Also provided are uses of 1,4-benzothiazepine derivatives in methods for treating and preventing atrial and ventricular cardiac arrhythmias and heart failure in a subject, and for preventing exercise-induced sudden cardiac death. The present invention also provides methods for identifying agents for use in treating and preventing atrial fibrillation and heart failure, and agents identified by these methods.

Cardiomyopathy may be treated by distributing space-occupying agent within the myocardium in a pattern about one or more chambers of the heart, such that the space-modifying agent integrates into and thickens at least part of the cardiac wall about the chamber so as globally to reduce wall stress and stabilize or even reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function. Over time the relief of wall stress reduces oxygen consumption and promotes healing. Moreover, various long-term therapeutic effects may be realized depending on the properties of the space-occupying agent, including combinations with other therapeutic materials. Specific cardiac conditions treatable by these systems and methods include, for example, dilated cardiomyopathy (with or without overt aneurismal formations), congestive heart failure, and ventricular arrhythmias. Patterns of distribution of space-occupying agent within the myocardium for global resizing may also be used or augmented to treat localized conditions such as myocardial infarctions, overt aneurysm of the ventricular wall as typically forms in response to large transmural myocardial infarctions, and mitral regurgitation due to a noncompliant mitral valve. These techniques may also be used to treat localized conditions that may not yet have progressed to cardiomyopathy.

Devices, systems and methods for controlling (inhibiting or enabling) the delivery of electrotherapeutic signals to a heart using sensing of local and / or global ECG signals to detect ventricular arrhythmia or indication of possible ventricular arrhythmia in the heart. The devices, systems and methods process the sensed signals and are capable of delivering electroptherapeutic signals to the heart in the presence of a supra-ventricular arrhythmia such as atrial fibrillation and atrial flutter, while inhibiting the delivering electroptherapeutic signals in the presence of PVCs and / or extopic beats, and / or ventricular arrhythmia. The electrotherapeutic signals may include, among others, pacing signals and cardiac contractility modulating signals.

Method and apparatus for guiding ablative therapy of abnormal biological electrical excitation. The excitation from the previous excitatory wave is significant at the beginning of the next excitation. In particular, it is designed for treatment of fast cardiac arrhythmias. Electrical signals are acquired from recording electrodes, and an inverse dipole method is used to identify the site of origin of an arrhythmia. The location of the tip of an ablation catheter is similarly localized from signals acquired from the recording electrodes while electrical pacing energy is delivered to the tip of the catheter close to or in contact with the cardiac tissue. The catheter tip is then guided to the site of origin of the arrhythmia, and ablative radio frequency energy is delivered to its tip to ablate the site.

Cardiomyopathy may be treated by distributing space-occupying agent within the myocardium in a pattern about one or more chambers of the heart, such that the space-modifying agent integrates into and thickens at least part of the cardiac wall about the chamber so as globally to reduce wall stress and stabilize or even reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function. Over time the relief of wall stress reduces oxygen consumption and promotes healing. Moreover, various long-term therapeutic effects may be realized depending on the properties of the space-occupying agent, including combinations with other therapeutic materials. Specific cardiac conditions treatable by these systems and methods include, for example, dilated cardiomyopathy (with or without overt aneurismal formations), congestive heart failure, and ventricular arrhythmias. Patterns of distribution of space-occupying agent within the myocardium for global resizing may also be used or augmented to treat localized conditions such as myocardial infarctions, overt aneurysm of the ventricular wall as typically forms in response to large transmural myocardial infarctions, and mitral regurgitation due to a noncompliant mitral valve. These techniques may also be used to treat localized conditions that may not yet have progressed to cardiomyopathy.

Methods and apparatus for a three-stage ventricular cardioversion and defibrillation therapy that treats ventricular tachycardia and fibrillation at low energy levels. An implantable therapy generator adapted to generate and selectively deliver a three-stage ventricular therapy and at least two leads operably each having at least one electrode adapted to be positioned proximate the ventricle of the patient. The device is programmed to deliver a three-stage therapy via both a far-field configuration and a near-field configuration of the electrodes upon detection of a ventricular arrhythmia. The three-stage therapy includes a first stage for unpinning of one or more singularities associated with the ventricular arrhythmia, a second stage for anti-repinning of the one or more singularities, both of which are delivered via the far-field configuration of the electrodes, and a third stage for extinguishing of the one or more singularities associated delivered via the near-field configuration of the electrodes.

Techniques identify origins of ventricular arrhythmias (e.g., ventricular tachycardia or premature ventricular complexes) including exit sites or other sites using a single or multi-lead electrocardiogram (ECG) assembly. The ECG assembly is used to map an organ into a series of different three-dimensional (3D) regions. Pace maps or ventricular arrhythmia signals are used in form of ECG signals along with a supervised learning methods to pinpoint the potential origin of VT, i.e., exit sites, in the various regions.

Methods and systems are provided for performing ventricular arrhythmia monitoring using at least two sensing channels that are each associated with different sensing vectors, for example by different pairs of extracardiac remote sensing electrodes. Myopotential associated with each of the sensing channels in monitored, and a ventricular arrhythmia monitoring mode is selected based thereon (e.g., based on determined myopotential levels). Ventricular arrhythmia monitoring is then performed using the selected monitoring mode.

Electrical stimulation to cardiac tissue stabilizes atrial and ventricular arrhythmia when timed to stabilize a limit cycle structure in a Poincare map. Disclosed are methods and apparatus, operational internally or externally, for removing the reentrant effects of heterogeneity present in a diseased heart and returning the heart to an improved metabolic status allowing removal of support. The methods and apparatus disclosed are also useful in the chronic surveillance and maintenance of regularized contractility in an aged or diseased heart.

Disclosed are uses of neuregulin in the preparation of medicines for preventing, treating or delaying ventricular arrhythmia of a human being, and pharmaceutical preparations that comprise the neuregulin and are used for preventing, treating or delaying the ventricular arrhythmia.